


RESEARCH

Open Access



Nanofibrillar cellulose wound dressing supports the growth and characteristics of human mesenchymal stem/stromal cells without cell adhesion coatings

Jasmi Kiiskinen¹, Arto Merivaara¹, Tiina Hakkarainen¹, Minna Kääriäinen², Susanna Miettinen^{3,4}, Marjo Yliperttula¹ and Raili Koivuniemi^{1*} 

Abstract

Background: In the field of regenerative medicine, delivery of human adipose-derived mesenchymal stem/stromal cells (hASCs) has shown great promise to promote wound healing. However, a hostile environment of the injured tissue has shown considerably to limit the survival rate of the transplanted cells, and thus, to improve the cell survival and retention towards successful cell transplantation, an optimal cell scaffold is required. The objective of this study was to evaluate the potential use of wood-derived nanofibrillar cellulose (NFC) wound dressing as a cell scaffold material for hASCs in order to develop a cell transplantation method free from animal-derived components for wound treatment.

Methods: Patient-derived hASCs were cultured on NFC wound dressing without cell adhesion coatings. Cell characteristics, including cell viability, morphology, cytoskeletal structure, proliferation potency, and mesenchymal cell and differentiation marker expression, were analyzed using cell viability assays, electron microscopy, immunocytochemistry, and quantitative or reverse transcriptase PCR. Student's *t* test and one-way ANOVA followed by a Tukey honestly significant difference post hoc test were used to determine statistical significance.

Results: hASCs were able to adhere to NFC dressing and maintained high cell survival without cell adhesion coatings with a cell density-dependent manner for the studied period of 2 weeks. In addition, NFC dressing did not induce any remarkable cytotoxicity towards hASCs or alter the morphology, proliferation potency, filamentous actin structure, the expression of mesenchymal vimentin and extracellular matrix (ECM) proteins collagen I and fibronectin, or the undifferentiated state of hASCs.

Conclusions: As a result, NFC wound dressing offers a functional cell culture platform for hASCs to be used further for in vivo wound healing studies in the future.

Keywords: Nanofibrillar cellulose, Adipose-derived mesenchymal stem/stromal cell, Cell transplantation, Cell scaffold, Regenerative medicine, Wound healing

* Correspondence: raili.koivuniemi@helsinki.fi

¹Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland
Full list of author information is available at the end of the article



Background

Wounds, which fail to heal in a timely manner for instance due to infection, tissue hypoxia, necrosis, or elevated levels of inflammatory cytokines, are classified as chronic wounds that are a heavy burden to healthcare systems, and which decrease the quality of life of the patients [1, 2]. Currently, treatment methods for chronic wounds are inefficient, and there is a high need for more advanced wound treatment therapies.

Mesenchymal stem/stromal cells (MSCs), such as human adipose-derived mesenchymal stem/stromal cells (hASCs), are multipotent and self-renewable progenitor cells that can be isolated from multiple sources and have been widely studied for the tissue engineering applications [3, 4]. However, the population of MSCs is heterogeneous, and they lack a specific cell surface marker [5]. Thus, MSCs are characterized according to three criteria from the International Society for Cellular Therapy: (1) their ability to adhere to plastic; (2) differentiate to adipocytes, osteoblasts, and chondrocytes under standard *in vitro* conditions; and (3) their expression of specific surface markers CD73, CD90, and CD105. MSCs must also express only low levels of major histocompatibility complex (MHC) class II molecules [5–9].

Human ASCs are isolated from a stromal vascular fraction (SVF) obtained from a lipoaspirate [10]. These cells have shown to have immunomodulatory properties via paracrine signaling and extracellular vesicles [11, 12]. Due to these properties, hASCs have been tested in multiple preclinical and clinical settings for instance for the treatment of autoimmune disease and graft-versus-host disease [13–15]. The immunomodulatory properties make them also suitable for allogenic and even xenogeneic transplantation. In addition, hASCs are especially suitable for wound healing applications due to their ability to secrete a wide variety of paracrine factors related to wound healing and due to their differentiation capability [16, 17]. *In vivo*, they have been shown to stimulate angiogenesis and to enhance wound closure [18, 19]. However, obstacles exist for successful cell transplantation including poor survival and low retention of cells in a target tissue, which typically is caused by the accumulation of cells in other tissues or enzymatic digestion of the single-cell suspension after systemic or topical administration [20, 21].

To overcome these issues, more emphasis has nowadays put on the development of biomaterial cell scaffold that would support cell survival and function. Nanofibrillar cellulose (NFC) is a wood-derived biomaterial of which properties make it an attractive option as a cell scaffold for biomedical applications. NFC commonly manufactured from wood pulp is non-toxic, biocompatible in humans, and biodegradable in nature [22]. NFC forms viscous hydrogels even with low fibril concentrations due to the naturally high affinity of cellulose to water and

strong interactions between cellulose fibers. The dimensions of NFC fibers resemble the dimensions of natural collagen, and thus, the viscoelastic properties and diffusion of proteins from NFC resemble the properties of extracellular matrix, which make NFC hydrogel applicable for 3D cell culturing [23]. NFC hydrogel has been shown to improve the formation of 3D tumor spheroids and to support the pluripotency of stem cells spheroids [23–26]. In addition to 3D cell culturing, NFC hydrogels can be utilized in the controlled release of drugs [27, 28]. Furthermore, NFC hydrogel can be modified into different forms, such as films and dressings [29, 30].

We have previously shown in a clinical study that NFC-based wound dressing supports the healing of skin graft donor sites [29, 31]. In the present study, we evaluated the potential of NFC dressing as the cell scaffold material for hASCs to be used as a cell transplantation method in the future. Our hypothesis was that NFC dressing offers a culture platform for hASCs and supports their survival and characteristics.

Methods

Materials

Human ASCs were isolated from adipose tissue samples acquired from surgical procedures at the Department of Plastic Surgery, Tampere University Hospital, with written informed consent. The study was carried out in accordance with the Ethics Committee of Pirkanmaa Hospital District, Tampere, Finland (R15161). Three different NFC wound dressings, type 1 and 3 NFC dressings and type 4 NFC dressing (FibDex®), were kindly supplied by UPM-Kymmene Corporation (UPM), Finland. All dressings were manufactured from unmodified wood-based NFC as described previously by Hakkarainen et al. [29] and Koivuniemi et al. [31].

Cell isolation and characterization

Cell isolation and characterization were performed as described previously by Kyllönen et al. [32]. The hASCs were obtained from subcutaneous adipose tissue of 12 donors (11 females, 1 male; mean age 56.7 ± 7.9) using Dulbecco's modified Eagle's medium/Ham's Nutrient Mixture F-12 (DMEM/F12; Thermo Fisher Scientific, USA), 5% (*v/v*) human serum (HS; PAA Laboratories, Austria), 1% (*v/v*) penicillin/streptomycin (PS; Invitrogen, USA), and 1% (*v/v*) L-alanyl-L-glutamine (GlutaMAX, Invitrogen). After the isolation process, cells were characterized at passage 1 by their differentiation capability towards adipocyte and osteogenic lineages using Oil red and Alizarin red S stainings (Sigma-Aldrich, USA), respectively, as well as by cell surface marker expressions using flow cytometry as described previously by Vuornos et al. [33]. The results indicated a mesenchymal origin of the isolated hASCs (see Additional file 2).

Cell culture

Cells were utilized between passages 3 and 6, and all experiments were repeated with cells isolated from individual donors (*n* numbers refer to the number of donors, which is the number of repeats of separate experiments). Used cell densities varied between 10,000 cells/cm² (10k) and 500k. Cells were cultured in MEM- α Supplement medium (MEM- α ; Gibco, UK) with 6% of human serum (*v/v*) (HS; Sigma-Aldrich) at + 37 °C and 5% CO₂.

Cell culture and adherence with NFC dressing

Cells were cultured on the patterned side of three different NFC dressings without cell adhesion coatings. For cell viability, adherence, and PCR assays, cells were cultured with NFC dressings on low-adhesion 96-well inertGrade BRANDplates[®] (Sigma-Aldrich) and cells cultured on normal tissue culture plastic well plates (SARSTEDT, Germany) served as a control. For scanning electron microscopy (SEM), transmission electron microscopy (TEM), and immunocytochemistry (ICC), cells were cultured on eight-chamber slides (Chamber Slide™ system 8-well Permanox slide plates, Nunc™ Lab-Tek™; Thermo Fisher Scientific) and cells cultured on cover glasses served as controls. Cell adherence for type 3 NFC dressing was evaluated calculating the number of non-adhered cells from the collected culture medium at several time points using a Bürker chamber.

Cell viability

Cell viability was evaluated by mitochondrial activity and released lactate dehydrogenase (LDH) on three different NFC dressings. Mitochondrial activity was evaluated with alamarBlue™ Cell Viability Reagent (Invitrogen) by adding 100 μ l of alamarBlue™ solution diluted with culture media to a final volume of 10% (*v/v*) to the cells and incubating for 3 or 4 h at + 37 °C. After the incubation, 80 μ l of the solution was transferred to a black 96-well plate (Nunc[®] MicroWell 96 optical bottom plates; Sigma-Aldrich), and fluorescence was measured using Varioskan LUX (Thermo Scientific, USA) and SkanIt RE- program 5.0 (excitation 560 nm, emission 590 nm). The fluorescence signal was normalized to the signal from control cells and blank control samples without cells.

Released LDH was evaluated with Pierce™ LDH Cytotoxicity assay kit (Thermo Scientific). The released LDH was measured using the chemical compound-mediated cytotoxicity assay according to the manufacturer's instructions. To prepare the spontaneous LDH activity controls, 2-h incubation of sterile ultrapure water added to cells was used for day 1 measurement, while overnight incubation was used for day 3 and day 5 measurements. Absorbances were measured at 490 nm and 680 nm using Varioskan LUX and SkanIt RE program 5.0, respectively. Cytotoxicity results were calculated

according to the manufacturer's instructions by normalizing the signal from samples to the signal from spontaneous LDH activity controls and maximum LDH release controls.

Electron microscopy

For scanning electron microscopy (SEM), cells were seeded on type 3 NFC dressing and fixed on day 7 with 2% glutaraldehyde (Sigma-Aldrich) in PBS for 2 h at room temperature (RT). Samples were coated with platinum, and the imaging was performed with FEI Quanta 250 Field Emission Gun SEM using 4.0–5.0 kV and 2.0–4.0 spot in high vacuum.

For transmission electron microscopy (TEM), cells were seeded on type 3 NFC dressing and fixed on day 7 with 2% glutaraldehyde in 0.1 M sodium phosphate buffer pH 7.4 for 2 h at RT. Imaging was performed with Jeol JEM 1400 Tungsten Electron gun TEM using 80.0 kV.

Immunocytochemistry

Cells were seeded on type 3 NFC dressing and fixed with 4% paraformaldehyde (PFA) for 20 min on day 1 or 7. After that, cells were washed three times with 0.1% (*v/v*) Tween 20 detergent (Sigma-Aldrich) in 1 \times Dulbecco's phosphate-buffered saline without calcium and magnesium (DPBS; Gibco). Blocking and permeabilization were performed using 0.1% (*v/v*) Triton X-100 in PBS containing 3% (*m/v*) bovine serum albumin (BSA; Sigma-Aldrich) and 0.3 M glycine (99%; Sigma-Aldrich) for 1 h at RT. Anti-mouse vimentin (1:50; Santa Cruz Biotechnology, USA), anti-rabbit Ki67 (1:200; Abcam, UK), anti-rabbit collagen α -1 (0.5 μ g/ml; BosterBio, USA), anti-mouse fibronectin (10 μ g/ml; R&D Systems, USA), and conjugated Phalloidin Alexa 488 (1:40; Thermo Fisher Scientific) antibodies in 0.1% (*v/v*) Tween 20 in DPBS containing 3% (*m/v*) BSA were added to the cells and incubated overnight at + 4 °C. On the following day, cells incubated with an unconjugated antibody were washed three times with washing buffer (0.1% (*v/v*) Tween 20 in DPBS) before adding Alexa Fluor 488 goat anti-mouse IgG (1:500; Life Technologies, USA) or Alexa Fluor 594 donkey anti-rabbit IgG (1:500; Life Technologies) in 0.1% (*v/v*) Tween 20 in DPBS containing 5% (*m/v*) BSA. Subsequently, all the cells were washed three times with washing buffer and once with 0.1 M Tris buffer pH 7.4. Cells were mounted with ProLong Diamond Antifade Mountant with DAPI (Life Technologies) and covered with cover glass (Menzel-Gläser, Germany). Samples were imaged with Aurox Clarity Laser Free Confocal HS wide-field microscopy and analyzed with ImageJ 2.0 software.

Quantitative PCR

Samples were prepared as described for cell viability assays. After 1-week culturing, cells were detached and washed twice with ice-cold DPBS before extracting total RNA using the RNeasy® Mini kit (Qiagen, Germany) according to the manufacturer’s instructions. cDNA was prepared from total RNA using High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific). Quantitative PCR (qPCR) reactions were performed using Fast SYBR® Green Master Mix (Applied Biosystems, USA) in a total volume of 20 µl, using 2 µl of cDNA as a template. Assays were run in triplicate including a non-template control (water) and a non-amplification control (no SYBR® Green) and using StepOnePlus detection system with StepOne Software v2.3. The following conditions were used: an initial activation and denaturation step of 95 °C for 30 s and 40 amplification cycles consisting of 95 °C for 5 s, 60 °C for 15 s, 72 °C for 10 s, and 72 °C for 1 min. Gene expression levels were analyzed using the relative standard curve method, with twofold serial dilutions of a control sample prepared for the standard curve. β-2-Microglobulin (β-2-m) was used as an endogenous control gene. The used primer sequences are given in Table 1.

Reverse transcriptase PCR

Total RNA from cells was prepared and used for cDNA synthesis as described above. Reverse transcriptase (RT) PCR for *CD45* was performed using *Taq* DNA polymerase (Invitrogen) and the following conditions: 95 °C for 3 min, 95 °C for 30 s, 62 °C for 30 s, 72 °C for 1 min, and 72 °C for 5 min, for 35 cycles, and including a non-template control (NTC; water). The primer sequences for *CD45* are given in Table 1.

Statistical analysis

Significant differences between the two groups were analyzed using Student’s *t* test and differences between three and more groups using one-way ANOVA followed by a Tukey HSD post hoc test. Values of *p* < 0.05 were considered statistically significant.

Results

Type 3 NFC dressing offers a culture platform for hASCs

To evaluate the effect of NFC on the cell viability of hASCs, the cells were cultured on NFC dressings (Fig. 1a) for 7 days. During the culturing with 30k–125k cell densities, hASCs showed low cell viabilities with each dressing type (see Additional file 3 A-C). When the different NFC dressings were compared with each other, type 3 NFC dressing showed the highest and type 1 NFC dressing the lowest cell viabilities, while any of the NFC dressings did not induce remarkable cell cytotoxicity with 50k–150k cell densities (see Additional file 3 D-F).

Table 1 Primer sequences used in quantitative and reverse transcriptase PCR assays

Gene	primer sequence 5'-3'
<i>CD73</i>	F: CTTAACGTGGGAGTGAACC R: TCTAGCTGCCATTGACAC
<i>CD90</i>	F: CGCTCTCTGCTAACAGTCTT R: CAGGCTGAACCTGACTGGA
<i>CD105</i>	F: CTAAGTGGCAGGGGAGACAG R: CTCCTATGTCGAGGAGCTA
<i>CD166</i>	F: ATTGAAGTTTTATTTGGCAGGAA R: GGCTTAGCCATGCAAAAACA
<i>CD34</i>	F: TCTGGATCAAAGTAGGCAGGA R: GATCCAGCCTCAGAGGAAGA
<i>CD45</i>	F: GCAAAGATGCCAGTGTCCACTT R: ATCTGAGGTGTTCGCTGTGATGG
<i>CCND1</i>	F: TATTGCGCTGCTACCGTTGA R: CCAATAGCAGCAAAATGTGAAA
<i>OCT4</i>	F: CAGTGCCCGAAACCCACAC R: GGAGACCCAGCAGCCTCAAA
<i>SOX2</i>	F: CTCGGGACATGATCAGC R: GGTAGTCTGGGACATGTGAA
<i>NANOG</i>	F: GCAGAAGGCCTCAGCACCTA R: GGTTCCAGTCGGGTTTAC
<i>PPARγ</i>	F: TCAGCGGAAGGACTTTATGTATG R: TCAGGTTTGGCGGATGC
<i>RUNX2</i>	F: GTCTTACCCCTCTACTCTGA R: TGCTTGCTCTTCTACTGA
<i>COL2A1</i>	F: CGTCCAGATGACCTTCTACG R: TGAGCAGGGCCTTCTGAG
<i>FGF2</i>	F: ATGGCAGCCGGGAGCATCACCCACG R: TCAGCTCTTCGAGACATTGGAAG
<i>TNF-α</i>	F: ATGAGCACTGAAAGCATGATCC R: GAGGGCTGATTAGAGAGAGGTC
<i>VEGF</i>	F: TGCTTCTGAGTTGCCAGGA R: TGTTTCAATGGTGTGAGGACATAG
<i>IL-6</i>	F: AACCTGAACCTTCCAAGATGG R: TCTGGCTTGTCTCTACTACT
<i>β-2-m</i>	F: CTCGCGTACTCTCTCTTTCTG R: GCTTACATGTCTCGATCCACT

Based on these results, type 3 and type 4 NFC dressings were chosen for further studies.

Scanning electron microscopy (SEM) was used to evaluate the effects of NFC dressings to the morphology of cells. Interestingly, by using cell densities of 300k and 500k, hASCs cultured on type 3 NFC dressing showed similar cell morphology and adhered monolayer throughout the dressing compared with the control cells cultured on a glass after 7 days of culturing (Fig. 1b). In contrast, with 150k and 200k cell densities, the cells appeared as small spherical cells growing distant from each other (see Additional file 4). Only very few cells were observed growing on type 4 NFC dressing, and thus, this dressing type was excluded from further studies.




Fig. 1 Culturing of hASCs on type 3 NFC dressing without cell adhesion coatings. SEM micrographs from **a** NFC dressings and **b** from hASCs cultured for 7 days with cell densities of 300,000 cells/cm² (300k) and 500k (*n* = 2). Similar morphology compared with the control cells were observed with both cell densities. Scale bars, 200 μm. Magnification, × 500. **c** Cell viability of hASCs with cell densities of 300k and 500k. High cell viabilities were observed especially with 300k cell density during 2-week culturing compared with the control cells cultured on plastic (all values are mean ± SEM, *n* = 3). **d** Majority of seeded cells adhered to the surface of type 3 NFC dressing within 24-h culturing. Compared with control cells, a lower number of adhered cells were observed only at 1-h time point (all values are mean ± SEM, *n* = 3, at 24 h time point *n* = 2). **p* < 0.05. NFC, nanofibrillar cellulose

As shown in Fig. 1c, high cell viabilities were observed over a 2-week culturing with 300k and 500k cell densities on type 3 NFC dressing. Only statistically significant decrease (**p* < 0.05) compared with control cells was detected on day 1 with 500k cell density. The highest cell viabilities were observed with 300k cell density that showed no remarkable cytotoxicity on day 4 (12.47 ± 1.61%) or day 7 (4.35 ± 0.88%). More than 97% of seeded cells (97.27 ± 2.49% for controls and 98.04 ± 1.50% for cells cultured on type 3 NFC dressing) were adhered within 24-h culturing (Fig. 1d). Compared with the control cells, cell adherence was statistically lower (**p* < 0.05) only at a time point of 1 h. Taken together, 300k cell density and type 3 NFC dressing appeared to offer the most optimal culture conditions for hASCs without cell adhesion coatings. These conditions were therefore used for the following experiments.


hASCs adhere to type 3 NFC dressing

Transmission electron microscopy (TEM) was used to study the interactions between hASCs and type 3 NFC dressing further. At 7 days of culture, hASCs were

shown to grow on type 3 NFC dressing with layered distribution, meaning that the cells grew partly on top of each other, which was also observed by SEM imaging. Interaction of hASCs with type 3 NFC dressing was confirmed to occur only on the patterned side of the dressing, the cells being adhered in the close vicinity of the patterns (Fig. 2a). A closer observation revealed interactions of cells with type 3 NFC dressing by focal adhesions (Fig. 2b, c). Therefore, it can be stated that hASCs were able to adhere to the type 3 NFC dressing.

The cytoskeletal structure and function of hASCs is maintained on type 3 NFC dressing

In order to study further, whether type 3 NFC dressing alters the properties of hASCs, their cytoskeletal structure and proliferation potency were addressed by immunocytochemical staining in order to visualize the filamentous actin (F-actin), mesenchymal vimentin, and proliferating cells by using antibody against Ki67. Vimentin staining revealed both polygonal and elongated cell morphologies both in control cells and in cells grown on type 3 NFC dressing, and proliferating cells



were present in both samples (Fig. 3a). However, the quantitated overall proliferation rate of hASCs on days 1 and 7 was remarkably low both in the control cells and in cells grown on type 3 NFC dressing. On day 7, phalloidin staining revealed an invariable structure of F-actin compared with the control cells (Fig. 3b).

The observation that hASCs maintained adherent during the culturing on type 3 NFC dressing suggested that they are capable of secreting their own extracellular matrix (ECM). The ECM formation was visualized by collagen I and fibronectin expression. As shown in Fig. 4, no difference in the expression of these ECM proteins was observed in hASCs after 1-week culturing on type 3 NFC dressing compared with the control cells. In addition, no difference in the organization of fibronectin

was observed (Fig. 4b). Taken together, hASCs maintained their cytoskeletal structure, proliferative nature, and expression of ECM proteins on type 3 NFC dressing.

hASCs maintain an undifferentiated state when cultured on type 3 NFC dressing

Expression of hASC-specific cell surface antigens, cell cycle and stemness markers, and differentiation markers was analyzed using qPCR. When culturing the cells with 300k cell density with or without type 3 NFC dressing, no statistically significant changes in the expression were observed for cell surface antigens *CD73*, *CD90*, *CD105*, *CD166*, or *CD34* (Fig. 5a) compared with the control cells of 30k cell density, which was considered as an optimal cell density for hASCs grown on tissue culture plastic. In addition, no statistically significant differences were observed in the expression of a positive cell cycle regulator *CCND1*; stemness markers *OCT4*, *SOX2*, and *NANOG*; an adipogenic marker gene *PPAR γ* ; an osteogenic marker *RUNX2*; or a chondrogenic marker *COL2A1* (Fig. 5a). In contrast to the positive expression of markers detected by qPCR, the expression of a specific cell surface antigen *CD45* analyzed by RT-PCR was absent in hASCs regardless of the culture condition (Fig. 5b).

Enzyme-linked immunosorbent assay (ELISA) was used to measure the amount of growth factors and cytokines secreted by hASCs cultured on type 3 NFC dressing. In the preliminary data measured from samples of a suboptimal low cell density, no secretion of various cytokines, including interleukin (IL)-4, IL-5, IL-10, and IL-12p70; interferon (IFN)- γ ; epidermal growth factor (EGF); vascular endothelial growth factor (VEGF); transforming growth factor (TGF) β -1; and granulocyte colony-stimulating factor (G-CSF), was detected with conditions applied in this study (Additional file 1). However, a statistically significant increase was detected in fibroblast growth factor (FGF)-2 ($p = 0.0032$), IL-6 ($p = 0.025$), and tumor necrosis factor (TNF)- α ($p = 0.012$) secretion levels (see Additional file 5). After discovering the optimal culture conditions for hASCs on type 3 NFC dressing, the expression of these cytokines were further analyzed using qPCR assay. In contrast to the preliminary ELISA results, no statistically significant increase was observed in *FGF2*, *TNF- α* , or *IL-6* expression levels with a higher cell density that showed equal expression levels compared with control cells (Fig. 6). Further, the expression of *VEGF* was quantitated as an additional growth factor, given its importance in wound healing process. No significant difference was detected in the expression of *VEGF* in hASCs cultured on NFC dressing compared with control cells. Consequently, type 3 NFC dressing did not alter the cytokine expression or undifferentiated state of hASCs.




Fig. 3 hASCs cultured on type 3 NFC dressing for 7 days. **a** Cells expressing the mesenchymal vimentin (vimentin; green) and showing proliferation capacity (Ki67; red). **b** F-actin structure (phalloidin; green). DAPI, blue. $N = 2$. Scale bars, 50 μm . Magnification, $\times 63$. NFC, nanofibrillar cellulose

Discussion

We have previously shown in a clinical study that NFC wound dressing performs comparably with a commercial wound dressing for the treatment of skin graft donor sites [31]. In the current project, we studied the potential use of NFC dressing as a cell-culturing platform for multipotent hASCs in order to develop cell transplantation method free from animal-derived components for wound care. To that end, we analyzed hASCs cultured with various cell densities on three different NFC wound dressings previously studied in patients.

hASCs are well established to promote wound healing [34]. However, the survival rate of the transplanted cells has shown to be diminished by the inflammatory response at a transplantation site [35, 36]. Therefore, a special consideration should be made to improve cell survival and retention towards successful cell therapy in the future, for instance, by using biomaterials as a cell scaffold. In previous studies, hASCs cultured with biomaterials have shown to promote wound healing in vivo [37–39]. However, different animal-derived components used in the scaffold and cell culture media or as cell adhesion coatings limit the translation of new tissue engineering innovations to clinical applications [40]. The potential of NFC dressing for a cell transplantation method to be applied in wound care is increased considerably due to the exclusion of all the animal-derived materials from the biomaterial. Consequently, our study is in good agreement with the recommendations of the Food and Drug Administration (FDA) [41].

Differing properties of biomaterials, caused by different manufacturing processes, are well known to alter the function of cells [42–45]. In this study, three different NFC dressings varying in topography and amount of

NFC were studied with multiple cell densities in order to identify the optimal culture conditions for hASCs. As a result, type 3 NFC dressing was observed to offer functional cell culture conditions with 300k cell density and without cell adhesion coatings according to the cell viability assays and SEM. Type 3 NFC dressing did not induce any remarkable cytotoxicity [46], and hASCs adhered to the surface of type 3 NFC dressing within 24 h and showed similar morphology compared with the control cells after 1-week culturing. However, the used cell density was excessively higher compared with the traditionally used cell densities that have been identified to affect the growth and functionality of cells [47–49]. In specific, high cell density has been shown to promote paracrine action of hASCs [49], which might benefit the wound repair process. Nevertheless, hASCs maintained high cell viability during the 2-week culturing. However, cell viability was cell density-dependent, and an optimal culture of hASCs on type 3 NFC dressing required high cell density, which might limit the use of the dressing in some cell culture applications.

One of the most important functions of biomaterials for cell transplantation is their ability to support cell adhesion, which is mainly an outcome from the physiochemical properties of the surface of the material. In addition, these properties have been shown to control cell behavior [50]. We observed that hASCs seeded with 300k cell density on type 3 NFC dressing express similar flattened morphology compared with the control cells, which typically indicate relatively strong attachment to the surface [51, 52]. Similar results were not observed with lower cell densities or with other NFC dressing types, which highlights the importance of optimal cell density and material properties for cell attachment and growth [53].




Fig. 4 Type 3 NFC dressing did not alter the expression of ECM proteins of hASCs. Immunocytochemistry for hASCs cultured on type 3 NFC dressing for 7 days. Cells showing invariable formation of **a** collagen I (red) and **b** fibronectin (green) compared with the controls ($n = 3$). DAPI, blue. $\times 20$ magnification, scale bar 100 μm ; $\times 63$ magnification, scale bar 50 μm . NFC, nanofibrillar cellulose

Focal adhesions have been found to facilitate interactions between MSCs and a biomaterial [54]. Our results showed that hASCs mainly interact with type 3 NFC dressing on patterned sites through focal adhesions indicating a mechanical interaction between hASCs and the biomaterial. Focal adhesions are large protein complexes and a special form of cell linkage with ECM involving the cell cytoskeleton that provides necessary interactions, e.g., cell migration [55]. The result is in good agreement with the fact that hASCs maintained high cell viability and adherence during the culture and suggests that the contact with the biomaterial was functional. In a more detailed analysis of cell morphology, visualization of F-actin structure and mesenchymal vimentin expression revealed similar morphology and F-actin fiber alignment typical for fibroblast-like cells in hASCs grown on type 3 NFC dressing compared with control cells.

MSCs are well known for their capability to form their own ECM and thus provide stability [56, 57]. In our study, hASCs were shown to express ECM proteins collagen I and fibronectin after 1-week culturing, though collagen I only showed intracellular location. This finding suggests that hASCs are able to form ECM on type 3 NFC dressing. It is possible that the ECM production would be even more prominent during longer culturing periods.

To further characterize hASCs on type 3 NFC dressing, we addressed their expression of various marker genes. Similar expression levels were observed regarding specific cell surface antigens, and stemness and differentiation markers between hASCs cultured with or without type 3 NFC dressing. These results are in good agreement with the study of Mertaniemi et al. where they demonstrated that hASCs cultured on glutaraldehyde




Fig. 5 Type 3 NFC dressing did not alter the undifferentiated state of hASCs. **a** Quantitative PCR for hASCs cultured on type 3 NFC dressing for 7 days. Relative expressions normalized to the expression of endogenous control gene β -2-m for hASCs cultured with 300,000 cells/cm² (300k) cell density with (NFC 300k) or without (300k) type 3 NFC dressing for 7 days showing no statistical difference in the expression of specific cell surface antigens *CD73*, *CD90*, *CD105*, *CD166*, or *CD34*; cell cycle marker *CCND1*; stemness markers *OCT4*, *SOX2*, and *NANOG*; or differentiation markers *PPAR γ* , *RUNX2*, or *COL2A1* compared with 30k cell density. Ctrl 30k and 300k $n = 4$, NFC 300k $n = 3$. **b** Reverse transcriptase PCR. Negative expression of a specific cell surface antigen *CD45* was observed for hASCs regardless of the culture conditions. β -2-m, beta-2-microglobulin; NFC, nanofibrillar cellulose; NTC, non-template control

cross-linked nanocellulose threads coated with laminin or CELLstart™ maintained their expression of mesenchymal cell surface markers *CD29*, *CD44*, *CD73*, *CD90*, and *CD166* as well as lacked expression of *CD45* and genes involved in adipocyte maturation during 10-day culturing [58]. Taken together, it can be hypothesized that with the right cell density and physiochemical properties, NFC dressing supports the cell attachment, function, and undifferentiated state of hASCs.

Notwithstanding that high cell density has shown to affect the growth of the cells [59], hASCs maintained their

potency to proliferate at some level as analyzed by Ki67 and *CCND1* expression. hASCs reveal high donor-to-donor variance [60], which has shown to alter their expression profiles [61] and, in some cases, even the function of cells. For instance, *CD34*, which is a stem cell marker traditionally used to distinguish hASCs from other cell types in SVF during the isolation process [62, 63], has shown to alter the function of hASCs [64]. In a study made by Suga et al., *CD34+* hASCs exhibit shorter doubling time compared with the *CD34-* hASCs, which in contrast showed greater ability to differentiate towards




Fig. 6 Growth factor and cytokine expression of hASCs analyzed by quantitative PCR. Relative expressions for hASCs cultured with 300,000 cells/cm² (300k) cell density with (NFC 300k) or without (300k) type 3 NFC dressing for 7 days. No statistically significant difference was observed in the expression of wound healing-related *FGF2*, *TNF-α*, *IL-6*, and *VEGF* compared with 30k cell density. Ctrl 30k and 300k *n* = 4, NFC 300k *n* = 3. *FGF2*, fibroblast growth factor 2; *IL-6*, interleukin-6; *NFC*, nanofibrillar cellulose; *TNF-α*, tumor necrosis factor alpha; *VEGF*, vascular endothelial growth factor

adipogenic and osteogenic cell lineages [64]. The authors speculated that CD34 expression would correlate with the capability to replicate as well as with differentiation potential, stemness, and specific expression profiles of angiogenesis-related genes. hASC population used in our study showed positive expression of *CD34*, which might correlate to the maintained proliferation competence and undifferentiated state of hASCs. However, it is important to notice that the expression profile of hASCs can be altered also by culture conditions, methods, and time [63]. Moreover, Ahn et al. have shown that a rough surface topography and hydrophilicity of the biomaterial can promote the proliferative competence of hASCs [51]. With that in mind and due to the properties of type 3 NFC dressing, including high affinity to water and patterned surface, type 3 NFC dressing may support the competence of hASCs to proliferate [50].

Since hASCs have a natural capability to affect the wound healing process and to modulate the immune reaction by secreting a wide variety of cytokines and growth factors, we evaluated their inflammatory response by measuring pro-inflammatory cytokines IL-6 and TNF-α [65]. In addition, the angiogenic potential of hASCs was evaluated by measuring their expression of FGF2 and VEGF. In the preliminary results with lower cell densities, we observed increased FGF2, IL-6, and TNF-α secretion in cells grown on NFC dressing, which may indicate a reaction towards a foreign material [65], result from suboptimal cell density, or propose enhanced angiogenic potential and/or wound healing properties of hASCs on NFC [66]. On the other hand, the used gelatin coating on NFC dressing during the preliminary experiments may have influenced the results since gelatin has been shown to affect cell behavior and pro-inflammatory cytokine secretion [67]. Extremely low, if any, secretion levels of these proteins were observed in control samples, which may result from the lacking stimulation of cells by inflammatory factors [68]. In contrast, we discovered unchanged gene expression levels of *FGF2*, *TNF-α*, and *IL-6* in hASCs cultured on type 3 NFC dressing compared with control cells when using the higher cell density. Sukho et al. have shown that cell seeding density affects greatly to the cytokine and growth factor secretion levels of hASCs [49]. Further,

similar results have been observed by Patrikoski et al., who showed that different culture conditions modulate the immunological properties of hASCs [69]. Our results suggest that type 3 NFC dressing does not modify the bioactivity of hASCs with an optimal 300k cell density. That would be an advantage for potential future use of NFC dressing as a cell therapy method for wound care.

The used cell density of 300k applied in this work is in good agreement with *in vivo* studies, which already have indicated enhanced wound healing using MSCs. However, the used cell densities have varied widely between 2×10^5 and 2×10^6 cells/cm² per wound [17, 39, 70–72]. Even with 4×10^4 cells/cm² have shown to enhance wound healing in a clinical study performed with three patients [73]. However, a better understanding about the effect of different cell densities to the wound healing process is still lacking. In addition, the cell amount obtained from liposuctions needs to be taken into consideration when developing new clinical applications. For instance, in a study by Tarallo et al., the yield of hASCs from liposuction aspirate fluid was 8.3×10^5 cells/ml [74]. From a safe liposuction volume [75], the amount of cells would be sufficient for type 3 NFC dressing to be used in autologous cell transplantation even into the large wound areas. Therefore, it can be stated that the cell density of 300k is suitable for future use regarding wound treatment. However, further *in vitro* and *in vivo* studies are a warrant to be performed in the future to yield more knowledge of the effects of type 3 NFC dressing to hASCs and their potential in wound healing.

Conclusions

In this study, NFC wound dressing of a natural origin showed to offer a cell culture scaffold for hASCs without any animal-derived culture components or cell adhesion coatings. NFC dressing does not induce any remarkable cytotoxicity or alter the morphology, cytoskeletal structure, function, or undifferentiated state of hASCs. Based on these findings, NFC dressing offers a functional cell culture platform for hASCs. However, further *in vitro* and *in vivo* studies are required to understand better the effect of type 3 NFC dressing to the biological activity of hASCs and their effect on wound healing before translation to the clinical application.

Additional files

Additional file 1: Supplementary Materials and Methods of this study. (DOCX 40 kb)

Additional file 2: Flow cytometry analysis of cell surface markers of hASCs. *n*=12; **n*=4 (DOCX 13 kb)

Additional file 3: Culturing of hASCs on different NFC dressings without cell-adhesion coatings. Preliminary cell viability (A–C) and cytotoxicity (D–F) experiments with Type 1 NFC dressing (A, D), Type 3

NFC dressing (B, E), Type 4 NFC dressing (C, F) and with different cell densities showing low viabilities but no remarkable cytotoxicity (*n*=3). NFC; nanofibrillar cellulose (TIF 393 kb)

Additional file 4: Scanning electron microscopy micrographs of hASCs. Human ASCs cultured on Type 3 NFC dressing for seven days with 150 000 cells/cm² (150k) and 200k cell densities. Magnification 500x, scale bars 200 μm, *n*=2. NFC; nanofibrillar cellulose. (TIF 2272 kb)

Additional file 5: Preliminary growth factor and cytokine expression of hASCs cultured on Type 3 NFC dressing. Secreted quantities of **A**) FGF2 (*p*=0.0032), **B**) IL-6 (*p*=0.025) and **C**) TNF-α (*p*=0.012) by hASCs cultured on top of Type 3 NFC dressing showing statistically significant (**p* <0.05; ***p* <0.005, *n*=3–4) difference compared with controls. FGF2; fibroblast growth factor 2, IL-6; interleukin-6, NFC; nanofibrillar cellulose, TNF-α; tumor necrosis factor alpha, VEGF; vascular endothelial growth factor. (TIF 365 kb)

Abbreviations

ASC: Adipose-derived mesenchymal stem/stromal cell; BSA: Bovine serum albumin; DPBS: Dulbecco's phosphate buffered saline without calcium and magnesium; ECM: Extracellular matrix; EGF: Epidermal growth factor; ELISA: Enzyme-linked immunosorbent assay; F-actin: Filamentous actin; FDA: Food and Drug Administration; FGF2: Fibroblast growth factor 2; G-CSF: Granulocyte colony-stimulating factor; hASC: Human adipose-derived mesenchymal stem/stromal cell; HS: Human serum; ICC: Immunocytochemistry; IFN-γ: Interferon gamma; IL: Interleukin; LDH: Lactate dehydrogenase; MHC-II: Major histocompatibility complex class II molecules; MSC: Mesenchymal stem/stromal cell; NFC: Nanofibrillar cellulose; NTC: Non-template control; P/S: Penicillin/streptomycin; PFA: Paraformaldehyde; qPCR: Quantitative PCR; RT-PCR: Reverse transcriptase PCR; SEM: Scanning electron microscopy; SVF: Stromal vascular fraction; TEM: Transmission electron microscopy; TGFβ-1: Transforming growth factor beta-1; TNF-α: Tumor necrosis factor alpha; VEGF: Vascular endothelial growth factor; β-2-m: Beta-2-Microglobulin

Acknowledgements

UPM-Kymmene Corporation, Finland, is acknowledged for providing the NFC materials to this study. The authors also express their gratitude to Helsinki Electron Microscopy Unit and the Light Microscopy Unit (University of Helsinki) supported by Biocentre Finland for their excellent guidance regarding imaging and to Ms. Anna-Majja Honkala and Mrs. Sari Kalliokoski for their excellent technical assistance in hASC isolation, expansion, and characterization.

Authors' contributions

SM, MY and RK contributed to the conception and design of this study. JK, AM, TH, MK, SM, and RK contributed to the data collection. JK and RK contributed to the analysis and interpretation of the data. JK was a major contributor in writing the manuscript. All authors have critically read and revised the final manuscript and approved its submission for publication.

Funding

This work was supported by the Doctoral Program in Materials Research and Nanosciences (University of Helsinki), the Doctoral Program in Biomedicine (University of Helsinki), Business Finland, Academy of Finland, Orion Foundation professor pool, Alfred Kordelin Foundation, and the industry-driven Business Finland funded UPM-Wound-project.

Availability of data and materials

The data that support the findings of these results are available on request from the corresponding author.

Ethics approval and consent to participate

Cells used in this study were isolated from adipose tissue samples acquired from surgical procedures at the Department of Plastic Surgery, Tampere University Hospital, with written informed consent. The study was carried out in accordance with the Ethics Committee of Pirkanmaa Hospital District, Tampere, Finland (R15161).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland. ²Department of Plastic and Reconstructive Surgery, Tampere University Hospital, Tampere, Finland. ³Adult Stem Cell Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. ⁴Research, Development and Innovation Centre, Tampere University Hospital, Tampere, Finland.

Received: 7 July 2019 Revised: 15 August 2019

Accepted: 22 August 2019 Published online: 23 September 2019

References

- Velnar T, Bailey T, Smrkolj V. The wound healing process: an overview of the cellular and molecular mechanisms. *J Int Med Res*. 2009. <https://doi.org/10.1177/147323000903700531>.
- Guo S, DiPietro LA. Critical review in oral biology & medicine: factors affecting wound healing. *J Dent Res*. 2010. <https://doi.org/10.1177/0022034509359125>.
- Marfia G, Navone SE, Di Vito C, Ughi N, Tabano S, Miozzo M, et al. Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds. *Organogenesis*. 2015. <https://doi.org/10.1080/15476278.2015.1126018>.
- D'souza N, Rossignoli F, Golinelli G, Grisendi G, Spano C, Candini O, et al. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. *BMC Med*. 2015. <https://doi.org/10.1186/s12916-015-0426-0>.
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006. <https://doi.org/10.1080/14653240600855905>.
- Laitinen A, Oja S, Kilpinen L, Kaartinen T, Möller J, Laitinen S, et al. A robust and reproducible animal serum-free culture method for clinical-grade bone marrow-derived mesenchymal stromal cells. *Cytotechnology*. 2016. <https://doi.org/10.1007/s10616-014-9841-x>.
- DeLaRosa O, Dalemans W, Lombardo E. Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. *Curr Opin Biotechnol*. 2012. <https://doi.org/10.1016/j.copbio.2012.05.005>.
- Hocking AM, Gibran NS. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. *Exp Cell Res*. 2010. <https://doi.org/10.1016/j.yexcr.2010.05.009>.
- Bunnell BA, Betancourt AM, Sullivan DE. New concepts on the immune modulation mediated by mesenchymal stem cells. *Stem Cell Res Ther*. 2010. <https://doi.org/10.1186/s12916-010-0034-4>.
- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng*. 2001. <https://doi.org/10.1089/107632701300062859>.
- Lou G, Chen Z, Zheng M, Liu Y. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. *Exp Mol Med*. 2017. <https://doi.org/10.1038/emmm.2017.63>.
- Blazquez R, Sanchez-Margallo FM, de la Rosa O, Dalemans W, Álvarez V, Tarazona R, et al. Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells. *Front Immunol*. 2014. <https://doi.org/10.3389/fimmu.2014.00556>.
- Kim E-J, Kim N, Cho S-G. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. *Exp Mol Med*. 2013. <https://doi.org/10.1038/emmm.2013.2>.
- Baron F, Storb R. Mesenchymal stromal cells: a new tool against graft-versus-host disease? *Biol Blood Marrow Transplant*. 2012. <https://doi.org/10.1016/j.bbmt.2011.09.003>.
- Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. *Stem Cell Res Ther*. 2010. <https://doi.org/10.1186/s12916-010-0034-4>.
- Kim W, Park B, Sung J, Yang J, Park S, Kwak S, et al. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. *J Dermatol Sci*. 2007. <https://doi.org/10.1016/j.jdermsci.2007.05.018>.
- Nie C, Yang D, Xu J, Si Z, Jin X, Zhang J. Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis. *Cell Transplant*. 2011. <https://doi.org/10.3727/096368910X520065>.
- Heo SC, Jeon ES, Lee IH, Kim HS, Kim MB, Kim JH. Tumor necrosis factor- α -activated human adipose tissue-derived mesenchymal stem cells accelerate cutaneous wound healing through paracrine mechanisms. *J Invest Dermatol*. 2011. <https://doi.org/10.1038/jid.2011.64>.
- James I, Bourne D, Silva M, Havis E, Albright K, Zhang L, et al. Adipose stem cells enhance excisional wound healing in a porcine model. *J Surg Res*. 2018. <https://doi.org/10.1016/j.jsr.2018.03.068>.
- Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. *Circulation*. 2003. <https://doi.org/10.1161/01.CIR.0000084828.50310.6A>.
- Yang Z, He C, He J, Chu J, Liu H, Deng X. Curcumin-mediated bone marrow mesenchymal stem cell sheets create a favorable immune microenvironment for adult full-thickness cutaneous wound healing. *Stem Cell Res Ther*. 2018. <https://doi.org/10.1186/s13287-018-0768-6>.
- Klemm D, Kramer F, Moritz S, Lindström T, Ankerfors M, Gray D, et al. Nanocelluloses: a new family of nature-based materials. *Angew Chem Int Ed*. 2011. <https://doi.org/10.1002/anie.201100173>.
- Bhattacharya M, Malinen MM, Lauren P, Lou Y-R, Kuisma SW, Kanninen L, et al. Nanofibrillar cellulose hydrogel promotes three-dimensional liver cell culture. *J Control Release*. 2012. <https://doi.org/10.1016/j.jconrel.2012.06.039>.
- Malinen MM, Kanninen LK, Corlu A, Isoniemi HM, Lou Y-R, Yliperttula ML, et al. Differentiation of liver progenitor cell line to functional organotypic cultures in 3D nanofibrillar cellulose and hyaluronan-gelatin hydrogels. *Biomaterials*. 2014. <https://doi.org/10.1016/j.biomaterials.2014.03.020>.
- Lou Y-R, Kanninen L, Kuisma T, Niklander J, Noon LA, Burks D, et al. The use of nanofibrillar cellulose hydrogel as a flexible three-dimensional model to culture human pluripotent stem cells. *Stem Cells Dev*. 2014. <https://doi.org/10.1089/scd.2013.0314>.
- Rinner B, Gandolfi G, Meditz K, Frisch M-T, Wagner K, Ciarrocchi A, et al. MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line. *Sci Rep*. 2017. <https://doi.org/10.1038/s41598-017-02197-y>.
- Paukkonen H, Kunnari M, Laurén P, Hakkarainen T, Auvinen V, Oksanen T, et al. Nanofibrillar cellulose hydrogels and reconstructed hydrogels as matrices for controlled drug release. *Int J Pharm*. 2017. <https://doi.org/10.1016/j.ijpharm.2017.09.002>.
- Laurén P, Lou Y-R, Raki M, Urtti A, Bergström K, Yliperttula M. Technetium-99m-labeled nanofibrillar cellulose hydrogel for in vivo drug release. *Eur J Pharm Sci*. 2014. <https://doi.org/10.1016/j.ejps.2014.09.013>.
- Hakkarainen T, Koivuniemi R, Kosonen M, Escobedo-Lucea C, Sanz-Garcia A, Vuola J, et al. Nanofibrillar cellulose wound dressing in skin graft donor site treatment. *J Control Release*. 2016. <https://doi.org/10.1016/j.jconrel.2016.07.053>.
- Kolakovic R, Peltonen L, Laukkanen A, Hirvonen J, Laaksonen T. Nanofibrillar cellulose films for controlled drug delivery. *Eur J Pharm Biopharm*. 2012. <https://doi.org/10.1016/j.ejpb.2012.06.011>.
- Koivuniemi R, Hakkarainen T, Kiiskinen J, Kosonen M, Vuola J, Valtonen J, et al. Clinical study of nanofibrillar cellulose hydrogel dressing for skin graft donor site treatment. *Advances in Wound Care*. 2019. <https://doi.org/10.1089/wound.2019.0982>.
- Kyllönen L, Haimi S, Mannerström B, Huhtala H, Rajala KM, Skottman H, et al. Effects of different serum conditions on osteogenic differentiation of human adipose stem cells in vitro. *Stem Cell Res Ther*. 2013. <https://doi.org/10.1186/s12916-013-0165-2>.
- Vuornos K, Ojansivu M, Koivisto JT, Häkkinen H, Belay B, Montonen T, et al. Bioactive glass ions induce efficient osteogenic differentiation of human adipose stem cells encapsulated in gellan gum and collagen type I hydrogels. *Mater Sci Eng C*. 2019. <https://doi.org/10.1016/j.msec.2019.02.035>.
- Gadelkarim M, Abushouk AI, Ghanem E, Hamaad AM, Saad AM, Abdel-Daim MM. Adipose-derived stem cells: effectiveness and advances in delivery in diabetic wound healing. *Biomed Pharmacother*. 2018. <https://doi.org/10.1016/j.biopha.2018.08.013>.
- Sart S, Ma T, Li Y. Preconditioning stem cells for in vivo delivery. *Biores Open Access*. 2014. <https://doi.org/10.1089/biores.2014.0012>.
- Baldari S, Di Rocco G, Piccoli M, Pozzobon M, Muraca M, Toietta G. Challenges and strategies for improving the regenerative effects of mesenchymal stromal cell-based therapies. *Int J Mol Sci*. 2017. <https://doi.org/10.3390/ijms18102087>.
- Wu Y-Y, Jiao Y-P, Xiao L-L, Li M-M, Liu H-W, Li S-H, et al. Experimental study on effects of adipose-derived stem cell-seeded silk fibroin chitosan film on wound healing of a diabetic rat model. *Ann Plast Surg*. 2018. <https://doi.org/10.1097/SAP.0000000000001355>.

38. Kaisang L, Siyu W, Lijun F, Daoyan P, Xian CJ, Jie S. Adipose-derived stem cells seeded in Pluronic F-127 hydrogel promotes diabetic wound healing. *J Surg Res*. 2017. <https://doi.org/10.1016/j.jss.2017.04.032>.
39. Nambu M, Kishimoto S, Nakamura S, Mizuno H, Yanagibayashi S, Yamamoto N, et al. Accelerated wound healing in healing-impaired db/db mice by autologous adipose tissue-derived stromal cells combined with atelocollagen matrix. *Ann Plast Surg*. 2009. <https://doi.org/10.1097/SAP.0b013e31817f01b6>.
40. Dayem AA, Lee S, Choi HY, Cho S-G. The impact of adhesion molecules on the in vitro culture and differentiation of stem cells. *Biotechnol J*. 2018. <https://doi.org/10.1002/biot.201700575>.
41. Medical devices containing materials derived from animal sources (except for in vitro diagnostic devices), guidance for FDA reviewers and industry; availability—FDA. Notice. 2019. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-containing-materials-derived-animal-sources-except-vitro-diagnostic-devices>. Accessed 5 Jul 2019.
42. Zhou K, Feng B, Wang W, Jiang Y, Zhang W, Zhou G, et al. Nanoscaled and microscaled parallel topography promotes tenogenic differentiation of asc and neotendon formation in vitro. *Int J Nanomedicine*. 2018. <https://doi.org/10.2147/IJN.S161423>.
43. Abagnale G, Steger M, Nguyen VH, Hersch N, Sechi A, Joussem S, et al. Surface topography enhances differentiation of mesenchymal stem cells towards osteogenic and adipogenic lineages. *Biomaterials*. 2015. <https://doi.org/10.1016/j.biomaterials.2015.05.030>.
44. Hiew VV, Simat SFB, Teoh PL. The advancement of biomaterials in regulating stem cell fate. *Stem Cell Rev Rep*. 2017. <https://doi.org/10.1007/s12015-017-9764-y>.
45. Menas AL, Yanamala N, Farcas MT, Russo M, Friend S, Fournier PM, et al. Fibrillar vs crystalline nanocellulose pulmonary epithelial cell responses: cytotoxicity or inflammation? *Chemosphere*. 2017. <https://doi.org/10.1016/j.chemosphere.2016.12.105>.
46. Basak V, Bahar TE, Ermine K, Yelda K, Mine K, Figen S, et al. Evaluation of cytotoxicity and gelatinases activity in 3T3 fibroblast cell by root repair materials. *Biotechnol Biotechnol Equip*. 2016. <https://doi.org/10.1080/13102818.2016.1192960>.
47. Thomas RJ, Chandra A, Liu Y, Houd PC, Conway PP, Williams DJ. Manufacture of a human mesenchymal stem cell population using an automated cell culture platform. *Cytotechnology*. 2007. <https://doi.org/10.1007/s10616-007-9091-2>.
48. Mareschi K, Rustichelli D, Calabrese R, Gunetti M, Sanavio F, Castiglia S, et al. Multipotent mesenchymal stromal stem cell expansion by plating whole bone marrow at a low cellular density: a more advantageous method for clinical use. *Stem Cells Intl*. 2012. <https://doi.org/10.1155/2012/920581>.
49. Sukho P, Kirpensteijn J, Hesselink JW, van Osch GJVM, Verseijden F, Bastiaansen-Jenniskens YM. Effect of cell seeding density and inflammatory cytokines on adipose tissue-derived stem cells: an in vitro study. *Stem Cell Rev Rep*. 2017. <https://doi.org/10.1007/s12015-017-9719-3>.
50. Bacakova L, Filova E, Parizek M, Ruml T, Svorcik V. Modulation of cell adhesion, proliferation and differentiation on materials designed for body implants. *Biotechnol Adv*. 2011. <https://doi.org/10.1016/j.biotechadv.2011.06.004>.
51. Ahn HH, Lee IW, Lee HB, Kim MS. Cellular behavior of human adipose-derived stem cells on wettable gradient polyethylene surfaces. *Int J Mol Sci*. 2014. <https://doi.org/10.3390/ijms15022075>.
52. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. *Cell*. 1996. [https://doi.org/10.1016/S0092-8674\(00\)81279-9](https://doi.org/10.1016/S0092-8674(00)81279-9).
53. Venugopal B, Mogha P, Dhawan J, Majumder A. Cell density overrides the effect of substrate stiffness on human mesenchymal stem cells' morphology and proliferation. *Biomater Sci*. 2018. <https://doi.org/10.1039/c7bm00853h>.
54. Pasquini G, Orrico C, Foroni L, Bonafè F, Carboni M, Guarnieri C, et al. Mesenchymal stem cell interaction with a non-woven hyaluronan-based scaffold suitable for tissue repair. *J Anat*. 2008. <https://doi.org/10.1111/j.1469-7580.2008.00974.x>.
55. Kim D-H, Wirtz D. Focal adhesion size uniquely predicts cell migration. *FASEB J*. 2013. <https://doi.org/10.1096/fj.12-220160>.
56. Colazzo F, Sarathchandra P, Smolenski RT, Chester AH, Tseng Y-, Czernuszka JT, et al. Extracellular matrix production by adipose-derived stem cells: implications for heart valve tissue engineering. *Biomaterials*. 2011; doi: <https://doi.org/10.1016/j.biomaterials.2010.09.003>.
57. Vielreicher M, Kralisch D, Vökl S, Sternal F, Arkudas A, Friedrich O. Bacterial nanocellulose stimulates mesenchymal stem cell expansion and formation of stable collagen-I networks as a novel biomaterial in tissue engineering. *Sci Rep*. 2018. <https://doi.org/10.1038/s41598-018-27760-z>.
58. Mertaniemi H, Escobedo-Lucea C, Sanz-García A, Gandía C, Mäkitie A, Partanen J, et al. Human stem cell decorated nanocellulose threads for biomedical applications. *Biomaterials*. 2016. <https://doi.org/10.1016/j.biomaterials.2015.12.020>.
59. Fossett E, Khan WS. Optimising human mesenchymal stem cell numbers for clinical application: a literature review. *Stem Cells Intl*. 2012. <https://doi.org/10.1155/2012/465259>.
60. Bodle JC, Teeter SD, Hluck BH, Hardin JW, Bernacki SH, Lobo EG. Age-related effects on the potency of human adipose-derived stem cells: creation and evaluation of superlots and implications for musculoskeletal tissue engineering applications. *Tissue Eng Part C Methods*. 2014. <https://doi.org/10.1089/ten.tec.2013.0683>.
61. Baer PC, Kuçi S, Krause M, Kuçi Z, Zielen S, Geiger H, et al. Comprehensive phenotypic characterization of human adipose-derived stromal/stem cells and their subsets by a high throughput technology. *Stem Cells Dev*. 2013. <https://doi.org/10.1089/scd.2012.0346>.
62. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. *Stem Cells*. 2006. <https://doi.org/10.1634/stemcells.2005-0234>.
63. Yoshimura K, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. *J Cell Physiol*. 2006. <https://doi.org/10.1002/jcp.20636>.
64. Suga H, Matsumoto D, Eto H, Inoue K, Aoi N, Kato H, et al. Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. *Stem Cells Dev*. 2009. <https://doi.org/10.1089/scd.2009.0003>.
65. Rydén L, Omar O, Johansson A, Jimbo R, Palmquist A, Thomsen P. Inflammatory cell response to ultra-thin amorphous and crystalline hydroxyapatite surfaces. *J Mater Sci Mater Med*. 2017. <https://doi.org/10.1007/s10856-016-5814-2>.
66. Yew T-L, Hung Y-T, Li H-Y, Chen H-W, Chen L-L, Tsai K-S, et al. Enhancement of wound healing by human multipotent stromal cell conditioned medium: the paracrine factors and p38 MAPK activation. *Cell Transplant*. 2011. <https://doi.org/10.3727/096368910X550198>.
67. Zhao Y-L, Lu Z-Y, Zhang X, Liu W-W, Yao G-D, Liu X-L, et al. Gelatin promotes cell aggregation and pro-inflammatory cytokine production in PMA-stimulated U937 cells by augmenting endocytosis-autophagy pathway. *Int J Biochem Cell Biol*. 2018. <https://doi.org/10.1016/j.biocel.2018.01.002>.
68. Lee DK, Song SU. Immunomodulatory mechanisms of mesenchymal stem cells and their therapeutic applications. *Cell Immunol*. 2018. <https://doi.org/10.1016/j.cellimm.2017.08.009>.
69. Patrikoski M, Sivula J, Huhtala H, Helminen M, Salo F, Mannerström B, et al. Different culture conditions modulate the immunological properties of adipose stem cells. *Stem Cells Transl Med*. 2014. <https://doi.org/10.5966/sctm.2013-0201>.
70. Hanson SE, Kleinbeck KR, Cantu D, Kim J, Bentz ML, Faucher LD, et al. Local delivery of allogeneic bone marrow and adipose tissue-derived mesenchymal stromal cells for cutaneous wound healing in a porcine model. *J Tissue Eng Regen Med*. 2016. <https://doi.org/10.1002/term.1700>.
71. Huang S-P, Hsu C-C, Chang S-C, Wang C-H, Deng S-C, Dai N-T, et al. Adipose-derived stem cells seeded on acellular dermal matrix grafts enhance wound healing in a murine model of a full-thickness defect. *Ann Plast Surg*. 2012. <https://doi.org/10.1097/SAP.0b013e318273f909>.
72. Assi R, Foster TR, He H, Stamati K, Bai H, Huang Y, et al. Delivery of mesenchymal stem cells in biomimetic engineered scaffolds promotes healing of diabetic ulcers. *Regen Med*. 2016. <https://doi.org/10.2217/rme-2015-0045>.
73. Maksimova N, Krashennikov M, Zhang Y, Ponomarev E, Pomytkin I, Melnichenko G, et al. Early passage autologous mesenchymal stromal cells accelerate diabetic wound re-epithelialization: a clinical case study. *Cytotherapy*. 2017. <https://doi.org/10.1016/j.jcyt.2017.08.017>.
74. Tarallo M, Fino P, Ribuffo D, Casella D, Toscani M, Spalvieri C, et al. Liposuction aspirate fluid adipose-derived stem cell injection and secondary healing in fingertip injury: a pilot study. *Plast Reconstr Surg*. 2018. <https://doi.org/10.1097/PRS.0000000000004506>.
75. Vieira BL, Chow I, Sinno S, Dorfman RG, Hanwright P, Gutowski KA. Is there a limit? A risk assessment model of liposuction and liposapitate volume on complications in abdominoplasty. *Plast Reconstr Surg*. 2018; doi: <https://doi.org/10.1097/PRS.0000000000004212>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.